The effects of dobutamine on the diameters of rat pial vessels were investigated in vivo using a closed cranial window technique. Dobutamine (10<SUP>-7</SUP>-10<SUP>-3</SUP> M) was dissolved in artificial cerebrospinal fluid (CSF). Arterioles (17-78 &micro;m in diameter) and venules (20-97 &micro;m in diameter) were observed through the cranial window over the left parietal cortex. Superfusion of the brain surface with only artificial CSF had no effect on vessel diameter. Dobutamine, even at a high concentration of 10<SUP>-4</SUP> M, did not induce significant diameter changes in the pial vessels, compared with control animals. The arterioles showed marked dilatation (+73%) during superfusion with 10<SUP>-3</SUP> M dobutamine (p &lt; 0.01 vs. control). The venules were also dilated (+12%), although the increased diameter was not statistically different from controls. Therefore, dobutamine did not induce a dose-dependent dilation. The results strongly suggest that dobutamine at clinical dosages does not have a direct vasomotor effect on brain microvessels.
Materials
and Methods
I. General preparation
Thirteen male Sprague-Dawley rats (Charles River Japan, Inc., Atsugi, Kanagawa), weighing 250-280 g, were used. Anesthesia was induced by 4% hal othane, which was reduced to 1.5% during catheter insertion into a tail artery and femoral veins. Fol lowing tracheotomy, a-chloralose (initial dose 80 mg/kg i.v.) was administered, and halothane was discontinued. Supplemental a-chloralose (15 mg/kg/ hr i.v.) was continuously given to maintain anesthe sia. The animals were immobilized with pancuro nium bromide (2 mg/kg/hr i.v.), and artificially ven tilated with room air and supplementary oxygen. Arterial blood was collected for blood-gas analyses and hematocrit measurements. Mean arterial blood pressure (MABP) in the tail artery and intracranial pressure (ICP) under the cranial window were re corded continuously. Fluid and drugs were adminis tered into the left femoral vein. Na+-fluorescein, used as a blood-brain barrier and vessel marker, was administered into the right femoral vein. Rectal temperature was maintained at 37.5'C by heating.
II.
Cranial window
The procedures of the cranial window will be men tioned briefly. A window was made over the left parietal brain using a dental drill, and a thin bone layer over the dura was left intact. Three catheters (PE 50) were attached to the window for superfusion of the brain surface and for ICP measurements. These were fixed in dental cement. A plexiglass fun nel was fixed to the skin above the window and filled with paraffin oil. Under the oil, the remaining bone layer of the window was removed, and the dura was opened. Following infusion of a small amount of artificial cerebrospinal fluid (CSF) over the brain, the window was closed by a glass cover (13 mm diameter) with cyanoacrylate. Finally, the funnel was removed, and the distal end of the out flow catheter of the window was adjusted to a height that maintained an ICP of 5 mmHg.
III.
Artificial CSF During and after a control period of at least 30 minutes, the brain surface was superfused with ar tificial CSF at 5 ml/hr. The artificial CSF was com posed of the following: glucose 3.3 mM, Na+ 158 mM, K+ 3.2 mM, Ca" 1.5 mM, C1 142 mM, Mg2+ 1.33 mM, and HCO3 24.5 mM, yielding an osmo lality of 307 mOsm/l. A mixture of humidified C02 (6%),02 (10%), and N2 (84%) was passed through the artificial CSF before superfusion at 37.50C, yield ing a pH of 7.32 ± 0.01 (range 7.30-7.36), a PCO2 of 46.1 ± 1.1 mmHg (42.2-49.4 mmHg), and a P02 of 86 ± 2 mmHg (80-92 mmHg). The pH of the solutions showed no changes after the addition of dobutamine.
IV.
Intravital fluorescence microscopy Intravital fluorescence microscopy was performed using a fluorescence microscope system.') Epi-illumi nation of the brain surface was made only during ob servation (about 10 min for each observation). A 100 W high pressure mercury lamp was used as the light source. Light intensity was reduced through two sets of ND25 filters. A band-pass filter was used to obtain an excitation source with a wavelength of 455-490 nm. The fluorescence emission of the brain surface after i.v. injection of 2% Na+-fluorescein was stud ied. Wavelengths below 515 nm were excluded dur ing both visual observation and photography. Dye so lution (10,ul) was administered for a total of 0.36 0.52 ml during each experiment. A 20 X objective lens was used to measure internal diameters of pial vessels, and images were recorded on videotape through a video timer. A low-light TV camera (C2741; Hamamatsu Photonics, Hamamatsu, Shizuo ka) and a TV-monitor provided the final magnifica tion (600 X). Extravasation of Na+-fluorescein was not observed during the entire observation period, demonstrating that the blood-brain barrier function was normal.
V.
Measurements of vessel diameters
Vessel diameters were measured off-line from hand-traced drawings of the vascular network on the brain surface from microphotographs taken through a 2 x objective lens. The diameters of ran domly selected arterioles and venules were manual ly measured on the TV monitor using sliding calipers (resolution on the TV monitor 0.01 mm). All measured locations were marked on the drawings to easily identify the exact site of each vessel. A total of 122 arterioles and 77 venules were studied in both drug-treated and control animals.
VI.
Experimental protocol Dobutamine, dissolved in artificial CSF, was serial ly diluted. Five different concentrations (10-7-10-3 M) were prepared prior to use. Five control animals were used to study the effects of continuous superfu sion of pial vessels with artificial CSF. The vessels were observed six times at 30-minute intervals, and the sequential changes in the diameters of 39 arteri oles (mean ± SD 42 ± 13,um, range 17-63 ,um) and 26 venules (mean ± SD 50 ± 19 ,um, range 20-95 ,um) were evaluated. In the remaining eight animals, the brain surface was superfused with the dobuta mine solution, and 83 arterioles (mean ± SD 42 --+ 15 ,um, range 20-78,um) and 51 venules (mean ± SD 44 ± 18,um, range 22-97 ,um) were evaluated. The test solutions were used in increasing concentra tions, and exposure of the cortical surface to any given concentration lasted for 30 minutes. 
Results

I. Physiological data
The blood-gas status was stable throughout all ex periments in all animals: PaCO2 was 37.4 ± 1.4 mmHg (range 35.1-41.0 mmHg), PaO2 was 116 ± 9 mmHg (96-145 mmHg), and pH was 7.43 ± 0.02 (7.37-7.49). The initial hematocrit (43 ± 2%) showed no significant difference to the final hematocrit (42 &plusmn; 3%). Heart rate and MABP are shown in Fig. 1 .
Both parameters were stable in the control animals. The heart rate of the dobutamine-treated animals following the superfusion of 10-3 M solution in creased by about 25 beats/min (p < 0.01 compared with the resting condition), but was not statistically different from the control group (p < 0.07). At the same time, the MABP of the treated animals tended to decrease although this was not significant (p < 0.20 vs. resting condition). Values are mean &plusmn; SD (rest = 100%). Dobutamine con centrations in experimental steps 1 to 5 were 10-7 to 10-3 M, respectively. 0: con trol, 39 vessels;
• : dobutamine, 83 vessels. *p < 0 .01 vs. rest. **p < 0.01 vs. control. Values are mean &plusmn; SD (rest = 100%). Dobutamine con centrations in experimental steps 1 to 5 were 10-7 to 10-3 M, respectively. 0: con trol, 26 vessels;
• : dobutamine, 51 vessels. * p < 0 .01 vs. rest.
II. Vessel diameter
Changes in the diameter of the pial vessels are shown in Figs. 2 The most prominent effect of dobutamine is a stimulatory effect on cardiac N1-adrenergic recep tors. Dobutamine can induce a marked increase in cardiac contractility, resulting in an increase in cardiac output, and also increases the heart rate to some degree, but not markedly. In the peripheral vas culature, dobutamine has minor stimulatory effects on both /32 and a-adrenergic receptors; /32-adrener gic dilator action being greater than the a-adrener gic constrictor action. Our present study shows that the heart rate increased with concomitant decrease of blood pressure when 10-3 M dobutamine was used (Fig. 1) . Apparently dobutamine in the artifi cial CSF had entered the systemic circulation, proba bly by absorption into the venous circulation (through the arachnoid villi) because of the ex tremely high concentration used. A similar phe nomenon was observed when ICP was elevated by 5-mmHg steps to exceed 25 mmHg.') Cerebral blood vessels may have both (x and fl receptors.", ', 12,17,19) The N1-receptor may be dominant, and may dilate cerebral vessels. 3.17,191 There is evidence suggesting the existence of the,82 receptor, although its action is unclear. 12,191 The in vivo effects of dobutamine on cerebral vessels have not been investigated previously, but in vitro ad ministration to cerebral arterial strips did not cause any response.") These results are consistent with the present study. Dobutamine apparently does not act on the #1-receptors on cerebral vessels, nor directly on the specific dopaminergic receptors on cerebral vessels.1s,2o1
Systemically administered catecholamines are believed to have only minimal effects on cerebral tis sue perfusion even when infused directly into the in ternal carotid artery,') possibly due to the blood brain barrier mechanisms for monoamines.11,141 An auto radiographic study has indicated that neither in travenous 14C-dobutamine nor dopamine can pene trate the blood-brain barrier.") We administered dobutamine extravascularly in the present study, and observed a marked arteriolar dilation during su perfusion with 10-'M dobutamine (Fig. 2) . This dila tion may have been secondary to absorption of the drug into the systemic circulation. Cardiac output may increase at the same time, but we did not meas ure the blood concentration of dobutamine, so the mechanisms causing the observed vessel dilatation are unclear. In addition, the relationship between augmentation in the cardiac output and changes in the cerebral blood flow has not been established.") Extravascularly administered dobutamine (10-7 to 10-4 M) did not change the diameters of pial vessels compared to a control group as observed through a cranial window in rats. The drug in a clinical dosage is unlikely to act directly on cerebral vessels. 
